Trilaciclib, The First-in-Class Myeoprotection: Market, Advantages, and Competitions 2023-09-15
In recent years, the concept of myeloprotection—protecting bone marrow from the damaging effects of chemotherapy—has emerged as a crucial component in cancer therapy. In the face of this evolving landscape, G1 Therapeutics' trilaciclib (marketed as COSELA®) stands out. Trilaciclib is the first thera
Read More